Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
8.1
USD
|
+3.85%
|
|
+1.89%
|
-67.40%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
602.8
|
485
|
1,085
|
672
|
854.7
|
281.9
|
-
|
-
|
Enterprise Value (EV)
1 |
527.6
|
373.5
|
895.6
|
422.9
|
854.7
|
149.7
|
100.6
|
79.14
|
P/E ratio
|
-2.79
x
|
-9.02
x
|
-14.5
x
|
-7.67
x
|
-8.15
x
|
-2.6
x
|
-2.61
x
|
-2.14
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
96.2
x
|
285
x
|
440
x
|
-
|
-
|
-
|
22.9
x
|
EV / Revenue
|
-
|
74.1
x
|
235
x
|
277
x
|
-
|
-
|
-
|
6.42
x
|
EV / EBITDA
|
-12.5
x
|
-7.17
x
|
-13.1
x
|
-4.99
x
|
-6.79
x
|
-1.14
x
|
-0.73
x
|
-0.57
x
|
EV / FCF
|
-
|
-
|
-14.5
x
|
-5.91
x
|
-
|
-1.31
x
|
-0.65
x
|
-0.38
x
|
FCF Yield
|
-
|
-
|
-6.9%
|
-16.9%
|
-
|
-76.3%
|
-154%
|
-264%
|
Price to Book
|
8.24
x
|
4.7
x
|
5.82
x
|
2.77
x
|
-
|
2.37
x
|
2.26
x
|
1.95
x
|
Nbr of stocks (in thousands)
|
21,831
|
24,555
|
29,546
|
33,940
|
34,396
|
34,800
|
-
|
-
|
Reference price
2 |
27.61
|
19.75
|
36.73
|
19.80
|
24.85
|
8.100
|
8.100
|
8.100
|
Announcement Date
|
3/30/20
|
3/11/21
|
3/10/22
|
3/14/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
5.042
|
3.813
|
1.527
|
-
|
-
|
-
|
12.32
|
EBITDA
1 |
-42.3
|
-52.09
|
-68.21
|
-84.75
|
-125.8
|
-131.7
|
-137.8
|
-139.3
|
EBIT
1 |
-43.63
|
-53.21
|
-69.21
|
-85.8
|
-127.1
|
-131.3
|
-162.3
|
-208.4
|
Operating Margin
|
-
|
-1,055.41%
|
-1,815.08%
|
-5,618.53%
|
-
|
-
|
-
|
-1,691.12%
|
Earnings before Tax (EBT)
1 |
-42.34
|
-51.9
|
-69.2
|
-83.84
|
-116.8
|
-123.9
|
-164
|
-249
|
Net income
1 |
-43
|
-52.89
|
-69.2
|
-83.84
|
-116.8
|
-129.3
|
-163.5
|
-240.3
|
Net margin
|
-
|
-1,049.03%
|
-1,814.95%
|
-5,490.37%
|
-
|
-
|
-
|
-1,949.97%
|
EPS
2 |
-9.890
|
-2.190
|
-2.530
|
-2.580
|
-3.050
|
-3.121
|
-3.102
|
-3.783
|
Free Cash Flow
1 |
-
|
-
|
-61.78
|
-71.62
|
-
|
-114.2
|
-155
|
-209
|
FCF margin
|
-
|
-
|
-1,620.27%
|
-4,689.98%
|
-
|
-
|
-
|
-1,695.74%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/20
|
3/11/21
|
3/10/22
|
3/14/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.966
|
0.756
|
0.641
|
0.886
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-17.8
|
-20.52
|
-18.64
|
-21.42
|
-24.18
|
-31.26
|
-28.1
|
-33.59
|
-32.89
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-18.53
|
-18.03
|
-20.78
|
-18.91
|
-21.68
|
-24.43
|
-31.56
|
-28.36
|
-33.92
|
-33.22
|
-32.81
|
-32.58
|
-32.54
|
-33.36
|
-29.75
|
Operating Margin
|
-1,918.53%
|
-2,385.45%
|
-3,241.34%
|
-2,134.2%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-18.65
|
-17.93
|
-20.47
|
-19.18
|
-21.24
|
-22.95
|
-29.27
|
-25.28
|
-31.37
|
-30.88
|
-30.54
|
-30.58
|
-30.61
|
-32.15
|
-29.2
|
Net income
1 |
-18.65
|
-17.93
|
-20.47
|
-19.18
|
-21.24
|
-22.95
|
-29.27
|
-25.28
|
-31.37
|
-30.88
|
-30.61
|
-31.24
|
-31.63
|
-33.64
|
-29.2
|
Net margin
|
-1,930.75%
|
-2,371.56%
|
-3,193.14%
|
-2,165.24%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6300
|
-0.6100
|
-0.6900
|
-0.6200
|
-0.6300
|
-0.6400
|
-0.7600
|
-0.6600
|
-0.8200
|
-0.8100
|
-0.8007
|
-0.8099
|
-0.7656
|
-0.7342
|
-0.7648
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/10/22
|
5/11/22
|
8/11/22
|
11/10/22
|
3/14/23
|
5/11/23
|
8/11/23
|
11/13/23
|
3/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
75.2
|
112
|
190
|
249
|
-
|
132
|
181
|
203
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-61.8
|
-71.6
|
-
|
-114
|
-155
|
-209
|
ROE (net income / shareholders' equity)
|
-62.7%
|
-59.7%
|
-47.6%
|
-38.9%
|
-
|
-91.5%
|
-75.5%
|
-53.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-43.6%
|
-36.1%
|
-
|
-57.7%
|
-41.3%
|
-
|
Assets
1 |
-
|
-
|
158.8
|
232.4
|
-
|
224
|
395.6
|
-
|
Book Value Per Share
2 |
3.350
|
4.210
|
6.310
|
7.160
|
-
|
3.410
|
3.580
|
4.150
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.89
|
0.4
|
0.76
|
0.85
|
-
|
2.16
|
2.23
|
3.52
|
Capex / Sales
|
-
|
7.89%
|
19.8%
|
55.34%
|
-
|
-
|
-
|
28.55%
|
Announcement Date
|
3/30/20
|
3/11/21
|
3/10/22
|
3/14/23
|
3/7/24
|
-
|
-
|
-
|
Average target price
22
USD Spread / Average Target +171.60% Consensus |
1st Jan change
|
Capi.
|
---|
| -67.40% | 282M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|